Found 12 matching trials
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
PHASE1This study is a single-center, open-label, dose-escalation study to observe...
Location
Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
PHASE1It is a single-center, open-labeled, single-arm, non-randomized investigato...
Location
Institute of Hematology & Blood Diseases Hospital
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
PHASE1It is a single-center, open-labeled, single-arm, non-randomized investigato...
Location
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
EARLY_PHASE1To evaluate the safety and tolerability of anti-GPRC5D-CD19 CAR-T cells inf...
Location
Guangdong Second Provincial General Hospital
BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma
EARLY_PHASE1This study is a single-arm, multicenter clinical trial of dose escalation a...
Location
Multiple Locations
Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL
PHASE1A Phase 1/2 Open label, multicenter, clinical trial of autologous CAR T-cel...
Location
Multiple Locations
Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)
PHASE2This is an open label, single-arm, Phase 2 study to evaluate the efficacy a...
Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
NAThis is a single-center, open-label, single-arm study to evaluate the safet...
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
PHASE1This study is a single-center, open-label, dose-exploration study to observ...
Location
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
PHASE1The is a first clinical study for Oricell Therapeutics Inc. in the United S...
Location
Northside Hospital